NDC product
Fycompa
NDC 69616-272 · Catalyst Pharmaceuticals, Inc.
Key facts
| Product NDC | 69616-272 |
|---|---|
| Proprietary name | Fycompa |
| Nonproprietary name | perampanel |
| Substances | PERAMPANEL |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Catalyst Pharmaceuticals, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA202834 |
| DEA schedule | CIII |
| Pharmacologic classes | AMPA Receptor Antagonists [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Noncompetitive AMPA Glutamate Receptor Antagonist [EPC], UGT1A9 Inhibitors [MoA], UGT2B7 Inhibitors [MoA] |
| Marketing start | Jan 2, 2024 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: